Resources
6 Results (showing 1 - 6)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 12/31/2019 (updated 3/28/2024)
To provide a procedure that both Nursing and Correctional Staff can adhere to for the orderly and secure issuance of suboxone.
Posted 7/13/2020 (updated 3/28/2024)
The Facts About Buprenorphine for Treatment of Opioid Addiction is available in many languages, including Spanish.
Posted 5/17/2021 (updated 4/10/2024)
FAQs About the New Buprenorphine Practice Guidelines
Buprenorphine Quick Start Guide
Buprenorphine Waiver Notification
Posted 4/26/2022 (updated 3/27/2024)
Overview of the jail-based Medication Assisted Treatment program within the Adult Detention Center in Fairfax County, Virginia.
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.